Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:80909 |
Name | castration-resistant prostate carcinoma |
Definition | A prostate carcinoma that is characterized by continued growth and spread despite the surgical removal of the testes or medical intervention to block androgen production. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer male reproductive organ cancer prostate cancer prostate carcinoma castration-resistant prostate carcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|---|---|---|---|
PTEN loss | Abiraterone + Ipatasertib | castration-resistant prostate carcinoma | sensitive | detail... |
PTEN loss | Enzalutamide + GSK2636771 | castration-resistant prostate carcinoma | no benefit | detail... |
PTEN inact mut | CC-115 + Enzalutamide | castration-resistant prostate carcinoma | predicted - sensitive | detail... |
PIK3CA act mut | CC-115 + Enzalutamide | castration-resistant prostate carcinoma | predicted - sensitive | detail... |
PTEN N323fs | Everolimus | castration-resistant prostate carcinoma | predicted - sensitive | detail... |
TSC2 inact mut | CC-115 + Enzalutamide | castration-resistant prostate carcinoma | predicted - sensitive | detail... |
TSC1 inact mut | CC-115 + Enzalutamide | castration-resistant prostate carcinoma | predicted - sensitive | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03436485 | Phase Ib/II | ODM-208 | Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-resistant Prostate Cancer (CYPIDES) | Active, not recruiting | USA | GBR | FRA | FIN | 0 |
NCT03903835 | Phase III | Docetaxel Cabazitaxel Carboplatin Abiraterone Enzalutamide | ProBio: A Biomarker Driven Study in Patients With Metastatic Castrate Resistant Prostate Cancer (ProBio) | Recruiting | SWE | NOR | CHE | BEL | 0 |
NCT04434482 | Phase I | Senaparib + Temozolomide | IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer | Completed | USA | AUS | 3 |
NCT04644770 | Phase I | JNJ-69086420 | A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer | Recruiting | USA | 0 |
NCT04717154 | Phase II | Ipilimumab + Nivolumab | Ipilimumab With Nivolumab for Molecular-selected Patients With Castration-resistant Prostate Cancer (INSPIRE) | Active, not recruiting | NLD | 0 |
NCT04839991 | Phase I | CB307 | Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours. (POTENTIA) | Recruiting | USA | NLD | GBR | ESP | 0 |
NCT04876651 | Phase III | Docetaxel Enzalutamide 177Lu-J591 + Abiraterone + Prednisolone Abiraterone + Prednisone 177Lu-J591 + Abiraterone + Prednisone 177Lu-J591 + Enzalutamide Abiraterone + Prednisolone 177Lu-J591 + Docetaxel | The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only | Recruiting | NZL | AUS | 0 |
NCT04926181 | Phase II | Apalutamide + Cetrelimab | Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer | Active, not recruiting | USA | 0 |
NCT04946370 | Phase Ib/II | Pembrolizumab 225Ac-J591 + Pembrolizumab | Maximizing Responses to Anti-PD1 Immunotherapy With PSMA-targeted Alpha Therapy in mCRPC | Recruiting | USA | 0 |
NCT05005728 | Phase II | XmAb20717 Olaparib + XmAb20717 Cabazitaxel + Carboplatin + XmAb20717 | XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer | Recruiting | USA | 0 |
NCT05057013 | Phase Ib/II | HMBD-001 | HMBD-001 in Advanced HER3 Positive Solid Tumours | Recruiting | GBR | 0 |
NCT05107674 | Phase I | NX-1607 | A Study of NX-1607 in Adults With Advanced Malignancies | Recruiting | USA | GBR | 0 |
NCT05159518 | Phase I | PRT2527 | A Study of PRT2527 in Participants With Advanced Solid Tumors | Completed | USA | 0 |
NCT05219500 | Phase II | FPI-2265 | Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST). (TATCIST) | Recruiting | USA | 0 |
NCT05241613 | Phase I | AC176 | A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer | Terminated | USA | 0 |
NCT05256381 | Phase II | Pembrolizumab + SOT101 | A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors | Active, not recruiting | USA | POL | ITA | HUN | FRA | ESP | CZE | BEL | 1 |
NCT05369000 | Phase Ib/II | LAVA-1207 | Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer | Recruiting | USA | NLD | ESP | 0 |
NCT05488548 | Phase I | NEO2734 | Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors | Recruiting | USA | 0 |
NCT05501548 | Phase II | Olaparib | Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer | Recruiting | USA | 0 |
NCT05534646 | Phase II | Apalutamide Apalutamide + Carotuximab | Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer | Recruiting | USA | 0 |
NCT05592626 | Phase Ib/II | STAR0602 | A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors (START-001) | Recruiting | USA | FRA | ESP | CAN | 0 |
NCT05655715 | Phase II | Ipilimumab + Nivolumab | Checkpoint Inhibitors and SBRT for mCRPC (CheckPRO) | Completed | DNK | 0 |
NCT05662397 | Phase Ib/II | HST-1011 Cemiplimab + HST-1011 | A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody | Recruiting | USA | 0 |
NCT05689021 | Phase II | Niraparib and abiraterone acetate + Prednisone | CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations | Recruiting | USA | 0 |
NCT05700669 | Phase Ib/II | AsiDNA + Olaparib | Study To Assess Safety And Efficacy Of AsiDNA In Combination With Olaparib In Participants With Recurrent Solid Tumors | Completed | USA | 0 |
NCT05730712 | Phase II | Enzalutamide + Pertuzumab/trastuzumab/hyaluronidase-zzxf | Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer, TraPPer Study | Recruiting | USA | 0 |
NCT05762536 | Phase II | Docetaxel Cabazitaxel + Darolutamide Darolutamide + Docetaxel Cabazitaxel | Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC (DAROTAXEL) | Recruiting | NLD | 0 |
NCT05785741 | Phase Ib/II | DB-1310 | A Phase 1/2a Study of DB-1310 in Advanced/Metastatic Solid Tumors | Recruiting | USA | 1 |
NCT05841563 | Phase I | PM54 | Clinical Trial of PM54 in Advanced Solid Tumors Patients. | Recruiting | USA | ESP | BEL | 0 |
NCT05914116 | Phase Ib/II | DB-1311 | A Study of DB-1311 in Advanced/Metastatic Solid Tumors | Recruiting | USA | AUS | 0 |
NCT05917470 | Phase Ib/II | ONCT-534 | A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer. | Terminated | USA | GBR | 0 |
NCT05999968 | Phase I | Abemaciclib + Darolutamide | Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment | Active, not recruiting | USA | ESP | DEU | 0 |
NCT06039371 | Phase II | Etoposide + Testosterone cypionate Carboplatin + Testosterone cypionate | Supraphysiological Androgen to Enhance Chemotherapy Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study | Recruiting | USA | 0 |
NCT06126731 | Phase Ib/II | Amoxicillin + Enzalutamide + Metronidazole Ciprofloxacin + Enzalutamide + Vancomycin | Combination Study of Antibiotics With Enzalutamide (PROMIZE) | Recruiting | GBR | CHE | 0 |
NCT06136624 | Phase III | Dexamethasone + Fludrocortisone + ODM-208 Enzalutamide Abiraterone | Study of MK-5684 Versus Alternative NHA in mCRPC (MK-5684-003) | Recruiting | USA | TUR | SWE | POL | NZL | NOR | NLD | ITA | ISR | IRL | HUN | GBR | FRA | FIN | ESP | DNK | DEU | CZE | CAN | BRA | AUT | AUS | ARG | 12 |
NCT06172478 | Phase II | Patritumab deruxtecan | A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors | Recruiting | USA | 2 |
NCT06190899 | Phase Ib/II | Darolutamide + Gedatolisib | Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer | Recruiting | USA | GBR | FRA | ESP | 0 |
NCT06200103 | FDA approved | lutetium Lu 177 vipivotide tetraxetan | Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer | Recruiting | USA | 0 |
NCT06216249 | Phase II | lutetium Lu 177 vipivotide tetraxetan | Evaluation of a Flexible Dosing Schedule of 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer | Recruiting | USA | 0 |
NCT06217822 | Phase I | BAY3563254 | First-in-human Study of 225Ac-PSMA-Trillium (BAY 3563254) in Participants With Advanced Metastatic Castration-resistant Prostate Cancer (mCRPC) (PAnTHA) | Recruiting | GBR | CAN | BEL | 0 |
NCT06228053 | Phase II | Enzalutamide + SX-682 | Study of SX-682 Plus Enzalutamide in Men With Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer (SYNERGY-201) | Recruiting | USA | 0 |
NCT06242470 | Phase I | MGC026 | A Study of MGC026 in Participants With Advanced Solid Tumors | Recruiting | USA | AUS | 0 |
NCT06253130 | Phase Ib/II | IMP1734 | A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors | Recruiting | USA | AUS | 2 |
NCT06305598 | Phase I | Leuprolide + Testosterone cypionate | Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer | Recruiting | USA | 0 |
NCT06334432 | Phase Ib/II | NUV-1511 | Safety and Efficacy Study of NUV-1511 in Adult Patients With Advanced Solid Tumors | Recruiting | USA | 0 |
NCT06401980 | Phase II | Docetaxel Radium Ra 223 dichloride 177Lu-rhPSMA-10.1 Darolutamide Olaparib Cabazitaxel | Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Recruiting | CHE | 0 |
NCT06492122 | Phase I | [225]Ac-FL-020 | Study With [225Ac]Ac-FL-020 in mCRPC Participants | Recruiting | AUS | 0 |
NCT06549465 | Phase II | 225Ac-J591 | Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer | Recruiting | USA | 0 |
NCT06551324 | Phase III | Enzalutamide + PF-06821497 Enzalutamide Docetaxel | A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). (MEVPRO-1) | Recruiting | USA | AUS | 3 |
NCT06560632 | Phase I | Olaparib + RP-3467 RP-3467 | Phase 1 Trial of RP-3467 Alone and in Combination With Olaparib in Participants With Advanced Solid Tumors (POLAR) | Not yet recruiting | USA | 0 |
NCT06576037 | Phase I | CBP-1019 + Enzalutamide CBP-1019 + Pembrolizumab Bevacizumab + CBP-1019 + Fluorouracil + Leucovorin + Oxaliplatin CBP-1019 + Fluorouracil + Leucovorin + Oxaliplatin | Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin | Not yet recruiting | USA | 0 |
NCT06582628 | Phase II | Enzalutamide Enzalutamide + Talazoparib | Talazoparib Plus Enzalutamide After Progression to Abiraterone in Metastatic Prostate Cancer: (TEAM PC) (TEAM PC) | Recruiting | ESP | 0 |
NCT06609005 | Phase I | Dexamethasone + Fludrocortisone + INV-9956 | A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer | Recruiting | USA | 0 |
NCT06616155 | Phase Ib/II | Enzalutamide + Ruxolitinib | Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer | Not yet recruiting | USA | 0 |
NCT06634849 | Phase Ib/II | PTT-4256 | An Open Label Dose Finding Study of PTT-4256 in Patients With Solid Tumours. | Recruiting | AUS | 0 |